OptiBiotix Heatlth demonstrates potential to boost health benefits of existing probiotics

Research presented by microbiologist Stephen O’Hara, CEO of OptiBiotix Health PLC (LON:OPTI), at the Microbiome R&D and Business Collaboration Congress: Asia in Hong Kong on the 1-2 March 2017 demonstrated that OptiBiotix’s microbiome modulators can increase the growth and biological effect of specific microbial species in the human microbiome.

The research was extremely well received at the conference, and OptiBiotix is speaking to a number of food manufacturers about incorporating its microbiome modulators into food products.

The oral presentation from OptiBiotix showed that its microbiome modulators have successfully increased the growth and biological effect of multiple species of microbe in human gut models, including their own cholesterol-reducing probiotic, LP-LDL.

By using the microbiome modulator, LPGOS, to increase the growth of LP-LDL, researchers reduced cholesterol as much as 27%.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Optibiotix Health Plc

    More articles like this

    Optibiotix Health Plc

    NutraIngredients Awards shortlist announced

    NutraIngredients is pleased to announce the shortlisted finalists for the 2018 edition of the NutraIngredients Awards … with the winners announced at our exclusive awards evening in Geneva on 16th May. The shortlisted finalistsfor the 10

    Optibiotix Health Plc

    OptiBiotix Health plc Launch of Slimbiome® in Nutri-bites®

    OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, and high cholesterol, today announced the launch of its award winning SlimBiome® in Nutri-Bites® with its US partner, Cereal Ingredients (“CII”), at the 2018 Natural

    Optibiotix Health Plc

    OptiBiotix Health PLC OptiBiotix Capital Reorganisation

    OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes announced on 28 November 2017 that it intended to seek a cancellation of its share premium account (the “Capital Reduction”) in

    Optibiotix Health Plc

    Optibiotix Health PLC In a Strong Position

    Optibiotix Health PLC (LON:OPTI) Chief Executive Officer Stephen O’Hara talks to tells Proactive Investors about focussing on the commercialisation of their technology across the company’s platforms.

    Optibiotix Health Plc

    Functional weight loss ingredient, SlimBiome brought to US

    OptiBiotix Health PLC (LON:OPTI), a specialist in the development of functional ingredients to modulate the human microbiome, has entered into a manufacturing and supply agreement with Cereal Ingredients. The agreement grants Cereal Ingredients a licence to

    Optibiotix Health Plc

    SlimBiome® – Supporting hunger-free weight management

    Slimbiome® is OptiBiotix’s patented combination of natural ingredients, identified and developed by leading experts in nutrition and metabolism, which supports scientifically substantiated weight loss claims. In independent tests the component ingredients have shown reductions in calorie intake

    Optibiotix Health Plc

    OptiBiotix Health PLC Proposed Directorate Changes

    OptiBiotix Health PLC (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, today announced that subject to the completion of normal regulatory due diligence Neil Davidson CBE will be appointed as Non- Executive Chairman on 1 January 2018. Adam Reynolds, the current Non-Executive Chairman will

    Optibiotix Health Plc

    Optibiotix Health PLC on Kelloggs’ Sugar Levels Cut

    Following the announcement today from Kelloggs to cut the amount of sugar in its three top selling children’s cereals, we caught up with Stephen O’Hara, CEO of OptiBiotix Health PLC (LON:OPTI) for his thoughts:   “We are really